Fauci Unfazed as Scientists Rely on Unproven Methods to Create COVID Vaccines
Teams are starting to test vaccines using messenger RNA or chimpanzee cold viruses to inoculate humans. Will their benefits last?
KHN’s ‘What The Health?’: Republicans in COVID Disarray
President Donald Trump’s sobering view of COVID-19 didn’t last long – this week, he was back to pushing hydroxychloroquine, a drug that has been shown not to work in treating the virus. Meanwhile, Republicans on Capitol Hill are still scrambling to agree among themselves and with the White House on the next coronavirus relief bill, as both a moratorium on evictions and extra unemployment payments expire. And the debate over drug prices, which was going to be one of the biggest health issues of this election year, makes a brief appearance. Alice Miranda Ollstein of Politico, Mary Ellen McIntire of CQ Roll Call and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss this and more. Also, Rovner interviews KHN’s Markian Hawryluk, who wrote the latest KHN-NPR “Bill of the Month” story about a surprise bill from a surprise surgical assistant.
Public Health Experts Fear a Hasty FDA Signoff on Vaccine
The FDA must approve any coronavirus vaccine before it’s widely distributed, but political pressure could cloud the decision.
Vacuna contra el coronavirus: ¿en qué punto está la investigación?
A principios de julio, había cerca de 160 ensayos de vacunas en todo el mundo, según la Organización Mundial de la Salud. Las tres vacunas más avanzadas se encuentran en la fase 3.
A Coronavirus Vaccine: Where Does It Stand?
Under ordinary circumstances, these phases of vaccine development can take years to complete. But now, during the age of coronavirus, the timeline is being shortened. Here’s an inventory of where things stand.
La tasa de vacunación contra la culebrilla aumenta, pero muchos quedan atrás
Un nuevo informe de los Centros para el Control y Prevención de Enfermedades (CDC) revela que el porcentaje de vacunación es mucho más bajo entre las minorías.
Shingles Vaccination Rate Soars But Leaves Many Behind
A federal study finds 35% of people 60 and older were vaccinated for shingles by 2018, up from 7% in 2008, but low-income people and those who are Black or Hispanic are far less likely to get vaccinated.
Analysis: How A COVID-19 Vaccine Could Cost Americans Dearly
The United States is the only developed nation unable to balance cost, efficacy and social good in setting prices.
Easy-breezy guest writer Rachel Bluth fills you in on a healthy dose of news from this past week.
KHN’s ‘What the Health?’: SCOTUS, Trump Collide Over Transgender Rights
The Trump administration rolled back protections for transgender patients just days before the Supreme Court cemented LGBTQ rights under the Civil Rights Act. So, what now? Meanwhile, coronavirus politics reaches beyond health care settings. Anna Edney of Bloomberg News, Tami Luhby of CNN and Shefali Luthra of KHN join KHN’s Julie Rovner to discuss this and more. Also, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
KHN senior correspondent Jordan Rau spins through this week’s essential health care news.
KHN executive editor Damon Darlin wades through mounds of health care policy stories — so you don’t have to.
KHN’s ‘What The Health?’: When It Comes To COVID-19, States Are On Their Own
Just about every state is lifting some coronavirus-related restrictions, but it’s unclear how things are really going, considering data on the spread of the virus lags and may not be reliable. Meanwhile, the federal government continues to throw more responsibility for dealing with the pandemic to state and local governments. Margot Sanger-Katz of The New York Times, Kimberly Leonard of Business Insider and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this and more.
Analysis: Get Ready For The Vaccine — They’re Never Simple
Trials are an immense undertaking involving tens of thousands of participants. They’re likely to start this summer — but don’t expect quick results. And what’s a successful result, anyway?
Drugmakers Tout COVID-19 Vaccines To Refurbish Their Public Image
Vaccines and antivirals have long been an afterthought but Johnson & Johnson and other firms are widely publicizing how they might stop COVID 19.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Persiguiendo el esquivo sueño de una cura para COVID-19
Hay más de 1,250 estudios de COVID-19 en marcha. Las farmacéuticas están invirtiendo miles de millones en el desarrollo de medicamentos y vacunas eficaces para poner fin a la pandemia.
Chasing The Elusive Dream Of A COVID Cure
Thousands of researchers worldwide are looking for a treatment that will go beyond what remdesivir can do for COVID patients.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
How The Pandemic And An Anti-Vax Health Official Are Roiling A Montana Community
In one conservative pocket of Montana, a local health board member who opposes vaccinations helped fight the state’s stay-at-home rules. But now, as the state slowly reopens, she faces a backlash of her own.
